November 9, 2018
 

Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-001-10D1: A novel humanized anti-HER3 antibody with a unique mechanism of action, demonstrates superior tumour inhibition in multiple tumour models compared to other EGFR family therapies” at the 30th European Organisation for Research and Treatment of Cancer, National Cancer Institute and American Association for Cancer Research symposium (EORTC-NCI-AACR) taking place in Dublin, Ireland on November 13-16, 2018.

HMBD-001-10D1 is a novel humanized anti-HER3 antibody developed using Hummingbird’s proprietary Rational Antibody Discovery platform to uniquely block a species-conserved functional interface on the HER3 protein to potently neutralize downstream growth signaling.
 
HER3 is known to activate MAPK and PI3K downstream signaling via heterodimerization with HER2 and EGFR and is a critical node in oncogenic signaling in Colon, Gastric, Breast, Pancreatic, Cervical, Melanoma and Head and Neck tumors. However, previous classes of anti-HER3 antibodies have shown only limited efficacy in patients as they bind regions of the HER3 protein that do not successfully prevent heterodimerization.
 
HMBD-001-10D1 has been shown to effectively block HER3 dimerization with HER2 and EGFR and inhibit downstream PI3K and MAPK signaling. HMBD-001-10D1 has also been engineered to induce increased Antibody Dependent Cell mediated Cytotoxicity and demonstrates superior tumor growth inhibition in in vitro and in vivo models compared to existing anti-HER3 antibodies. HMBD-001-10D1 has been shown to be safe and displays excellent bioavailability in animal studies.


HMBD-001-10D1 is wholly owned and developed by Hummingbird Bioscience.


For further information please email contact@hummingbirdbio.com


About Hummingbird Bioscience

Hummingbird Bioscience is an innovative biotechnology company, harnessing the potential of integrative biology to discover and develop novel cancer immuno-therapeutics.  We are focused on taking projects from validated target to clinical proof of concept. Our data and model driven integrative biology approach provide an unprecedented ability to understand and manipulate the immune system – allowing us to 1) Identify the right targets and mechanisms 2) Generate best in class antibodies against these targets 3) Characterize the effect of our drug candidates on the tumor and immune system at a molecular and cellular level, to better predict clinical outcomes of our drugs.  We have compelling pre-clinical data for four potential first in class therapeutic programs focused on the most exciting targets in oncology.